+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Monoclonal Antibodies for Non-small Cell Lung Cancer Market - Global Forecast 2026-2032- Product Image
Monoclonal Antibodies for Non-small Cell Lung Cancer Market - Global Forecast 2026-2032- Product Image
Sale

Monoclonal Antibodies for Non-small Cell Lung Cancer Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277793
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introduction: Monoclonal Antibodies in Non-Small Cell Lung Cancer

Monoclonal antibodies have become an important component of non-small cell lung cancer (NSCLC) care, particularly through immune checkpoint inhibition and targeted treatment of defined molecular or vascular pathways. Their clinical use depends on tumor histology, biomarker status, disease stage, prior therapy, patient fitness, and local treatment guidelines. The field is shaped by advances in pathology, immuno-oncology, combination regimens, and multidisciplinary care rather than by a single therapeutic approach.

Transformative Shifts Reshaping NSCLC Antibody Therapy

NSCLC treatment is shifting from histology-led decisions toward biomarker-informed treatment selection. Routine assessment of PD-L1 expression and molecular alterations increasingly informs first-line therapy, while broader genomic profiling can identify patients eligible for targeted options or clinical trials. Earlier use of immunotherapy, perioperative treatment strategies, and combination regimens is also changing care pathways, although toxicity management, diagnostic quality, and equitable access remain important constraints.

Artificial Intelligence’s Cumulative Impact on NSCLC Antibody Care

Artificial intelligence is contributing to NSCLC antibody development and delivery through digital pathology, radiology-assisted lesion assessment, biomarker interpretation, trial matching, and clinical workflow support. These applications may help standardize PD-L1 scoring, identify treatment-response patterns, and integrate clinical, imaging, and genomic information. However, performance depends on representative datasets, external validation, transparent governance, and clinician oversight; AI should support rather than replace multidisciplinary judgment and patient-specific decision-making.

Regional Insights Across the Global NSCLC Antibody Landscape

North America is characterized by rapid adoption of immuno-oncology, extensive clinical-trial activity, and comparatively sophisticated biomarker infrastructure, while affordability and coverage variation influence access. Europe combines strong guideline-based care with country-level differences in reimbursement, testing capacity, and health-system implementation. Asia-Pacific includes advanced treatment and diagnostic ecosystems alongside substantial access variation across economies. Latin America continues to expand oncology capabilities but faces constraints in pathology capacity, reimbursement, and geographic access. The Middle East is developing specialized cancer centers and precision-oncology services, with availability differing across health systems. Africa faces pronounced challenges in early diagnosis, molecular testing, specialist capacity, and sustained access to complex systemic therapies.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets show varied diagnostic readiness and uneven access to antibody-based therapies, making regional collaboration in testing, procurement, and clinical training important. BRICS countries combine substantial patient populations and growing oncology capabilities with significant differences in reimbursement, infrastructure, and regulatory pathways. The European Union benefits from shared scientific and regulatory cooperation, although national health-technology assessment and funding decisions remain distinct. G7 members generally have mature research, diagnostic, and treatment systems but continue to address cost, workforce, and outcome disparities. GCC countries are investing in specialized healthcare and precision oncology, while NATO members span highly diverse health systems, requiring tailored implementation rather than a uniform access model.

Country Insights: Diagnostics, Access, and Clinical Practice

Australia and Canada generally emphasize guideline-based care, multidisciplinary services, and biomarker testing, while geographic dispersion can affect timely access. Brazil and Mexico are expanding oncology capacity but experience differences between public and private delivery, regional availability, and diagnostic turnaround. China, India, Russia, and South Korea are developing distinct combinations of domestic research, specialized centers, and regulatory or reimbursement frameworks; access and testing remain heterogeneous within each country. France, Germany, Italy, Spain, and the United Kingdom operate mature clinical systems, yet national reimbursement, health-technology assessment, referral pathways, and testing practices differ. Japan combines advanced oncology expertise with established regulatory and clinical infrastructure, while the United States has extensive treatment and trial availability alongside pronounced insurance, affordability, and care-access variation.

Actionable Priorities for Leaders in NSCLC Antibody Care

Industry leaders should prioritize evidence generation that reflects real-world patients, including older adults, patients with comorbidities, and populations underrepresented in trials. Investment in validated biomarker testing, pathology quality systems, and rapid sample-to-result workflows can improve treatment selection. Organizations should also strengthen toxicity education, multidisciplinary coordination, patient support, and post-treatment monitoring. Regional strategies should account for reimbursement and infrastructure differences, while responsible use of AI requires documented validation, privacy safeguards, bias monitoring, and clear clinician accountability.

Research Methodology for the Executive Summary

This executive summary synthesizes established clinical and healthcare-system developments relevant to monoclonal antibodies for NSCLC. The approach considers treatment mechanisms, biomarker-driven selection, disease-stage pathways, diagnostic infrastructure, regulatory and reimbursement conditions, regional variation, and implementation barriers. Insights are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and company-specific claims. Interpretation should be updated as clinical guidelines, regulatory decisions, evidence standards, and access policies evolve.

Conclusion: Building More Precise and Equitable NSCLC Treatment

Monoclonal antibodies are central to the continuing evolution of NSCLC management, but their value depends on accurate diagnosis, appropriate patient selection, safe combination use, and reliable access. The next phase will be defined by integration of immunotherapy with molecular testing, earlier treatment strategies, evidence from routine practice, and carefully governed digital tools. Leaders that improve diagnostic quality, coordinate care, and address regional and socioeconomic barriers will be better positioned to translate therapeutic progress into consistent patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Therapy Class
7.1. Introduction
7.2. Checkpoint Inhibitors
7.3. Targeted Antibodies
7.4. Antibody-Drug Conjugates
7.5. Bispecific Antibodies
8. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Line of Treatment
8.1. Introduction
8.2. First-Line
8.3. Second-Line
8.4. Third-Line and Beyond
8.5. Maintenance and Consolidation Therapy
9. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Development Status
9.1. Introduction
9.2. Preclinical Candidates
9.3. Clinical Pipeline
9.4. Approved Products
10. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. Monoclonal Antibodies for Non-small Cell Lung Cancer Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Amgen Inc
14.2. AstraZeneca PLC
14.3. BeiGene Ltd
14.4. Boehringer Ingelheim International GmbH
14.5. Bristol-Myers Squibb Company
14.6. Daiichi Sankyo Company Limited
14.7. Eli Lilly and Company
14.8. F. Hoffmann-La Roche Ltd
14.9. Genmab A/S
14.10. GlaxoSmithKline plc
14.11. Innovent Biologics Inc
14.12. Johnson & Johnson
14.13. Merck & Co Inc
14.14. Merck KGaA
14.15. Merus N.V.
14.16. Novartis AG
14.17. Ono Pharmaceutical Co Ltd
14.18. Pfizer Inc
14.19. Regeneron Pharmaceuticals Inc
14.20. Sanofi S.A.
14.21. Seagen Inc
14.22. Takeda Pharmaceutical Company Limited
14.23. Zai Lab Ltd
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market, Years Considered for the Study
FIGURE 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market, Research Design
FIGURE 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market, Research Framework
FIGURE 4. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market, Data Triangulation
FIGURE 5. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2025 vs 2032 (%)
FIGURE 7. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2025 vs 2032 (%)
FIGURE 9. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2025 vs 2032 (%)
FIGURE 11. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Segmentation & Coverage
TABLE 2. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 3. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 4. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Targeted Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Targeted Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Targeted Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Antibody-Drug Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Antibody-Drug Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Antibody-Drug Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Bispecific Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Bispecific Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Bispecific Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 17. Global First-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global First-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global First-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Second-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Second-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Second-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Third-Line and Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Third-Line and Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Third-Line and Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Maintenance and Consolidation Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Maintenance and Consolidation Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Maintenance and Consolidation Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 30. Global Preclinical Candidates Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Preclinical Candidates Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Preclinical Candidates Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Clinical Pipeline Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Clinical Pipeline Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Clinical Pipeline Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Approved Products Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Approved Products Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Approved Products Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 43. Asia-Pacific Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 44. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 46. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 47. North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 48. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 50. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 51. Latin America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 52. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 54. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 55. Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 56. Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 58. Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 59. Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 60. Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 62. Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 63. Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 64. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. ASEAN Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. ASEAN Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 67. ASEAN Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 68. ASEAN Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 69. GCC Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. GCC Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 71. GCC Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 72. GCC Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 73. European Union Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. European Union Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 75. European Union Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 76. European Union Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 77. BRICS Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. BRICS Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 79. BRICS Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 80. BRICS Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 81. G7 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. G7 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 83. G7 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 84. G7 Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 85. NATO Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. NATO Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 87. NATO Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 88. NATO Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 89. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 91. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 92. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 93. United States Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 94. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 95. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 96. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 97. Canada Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 98. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 99. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 100. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 101. Mexico Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 102. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 103. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 104. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 105. Brazil Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 106. United Kingdom Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 107. United Kingdom Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 108. United Kingdom Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 109. United Kingdom Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 110. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 111. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 112. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 113. Germany Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 114. France Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 115. France Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 116. France Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 117. France Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 118. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 119. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 120. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 121. Russia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 122. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 123. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 124. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 125. Italy Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 126. Spain Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 127. Spain Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 128. Spain Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 129. Spain Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 130. China Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 131. China Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 132. China Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 133. China Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 134. India Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 135. India Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 136. India Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 137. India Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 138. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 139. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 140. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 141. Japan Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 142. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 143. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 144. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 145. Australia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 146. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, 2017-2032 (USD Million)
TABLE 147. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 148. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Line of Treatment, 2017-2032 (USD Million)
TABLE 149. South Korea Monoclonal Antibodies for Non-small Cell Lung Cancer Market Size, by Development Status, 2017-2032 (USD Million)
TABLE 150. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market Share, by Key Player, 2025
TABLE 151. Global Monoclonal Antibodies for Non-small Cell Lung Cancer Market, Key Experts

Companies Mentioned

  • Amgen Inc
  • AstraZeneca PLC
  • BeiGene Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline plc
  • Innovent Biologics Inc
  • Johnson & Johnson
  • Merck & Co Inc
  • Merck KGaA
  • Merus N.V.
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi S.A.
  • Seagen Inc
  • Takeda Pharmaceutical Company Limited
  • Zai Lab Ltd

Related Topics

Related Reports

Lung Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Lung Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
C Met Non-Small Cell Lung Cancer Pipeline Analysis Report 2025 - Product Image

C Met Non-Small Cell Lung Cancer Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Fully Humanized Monoclonal Antibody Market - Global Forecast 2026-2032 - Product Image

Fully Humanized Monoclonal Antibody Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Non-Small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 981 Pages
  • Global
From
PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025 - Product Image

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.